CHE
The good news first
Chemed’s second quarter looked a lot like a company doing two different jobs at once. VITAS, its hospice business, came in stronger than expected, which is the part investors usually care about most because it tends to set the tone for the whole name.
The plumber wasn’t exactly idling
Roto-Rooter also grew revenue, so this wasn’t some one-legged stool situation. But the business kept running into higher customer-acquisition costs, which is corporate-speak for: getting new customers wasn’t exactly a bargain-bin exercise.
Why you should care
That combo matters because Chemed’s story is less about flashy growth and more about whether its two core engines can keep the cash flowing without chewing through too much extra spending. If VITAS stays strong, it can offset the plumbing side’s cost pressure and keep the overall thesis intact.
Big picture
For investors, this was a pretty classic Chemed quarter: steady, a little messy, but not broken. The market will probably focus on whether VITAS can keep carrying the load while Roto-Rooter gets its marketing bill under control.